Welcome to our dedicated page for PHARMADRUG news (Ticker: LMLLF), a resource for investors and traders seeking the latest updates and insights on PHARMADRUG stock.
PharmaDrug Inc. (LMLLF) is a specialty pharmaceutical company focused on research, development, and commercialization of controlled-substances, natural medicines, and previously approved drugs. The company's subsidiary, SecureDose Synthetics Inc., has engaged with Chiral Labs to develop a novel cocaine manufacturing process. With a goal to provide safe supply programs and revolutionize the pharmaceutical supply chain, PharmaDrug is committed to developing biosynthetic drugs to combat substance abuse and contaminated street drugs.
Rhea-AI Summary
PharmaDrug's Sairiyo Therapeutics has finished the clinical and regulatory package for a Phase 1 study of their reformulated cepharanthine in Australia. This patented drug, PD-001, aims to treat infectious diseases and oncology. Sairiyo will conduct the study in Australia to benefit from drug development incentives, planning to submit an Investigational New Drug application to the FDA afterward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.89%
Tags
-
Rhea-AI Summary
PharmaDrug's SecureDose partners with Chiral Labs to advance novel cocaine manufacturing process, aiming to develop biosynthetic pharmaceutical-grade cocaine for safe supply programs. The project includes process refinement, test batch production, and potential commercial manufacturing collaboration. The agreement involves a fee rate of CAD 60,000 per month with an anticipated completion timeline of seven to nine months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.24%
Tags
-
Rhea-AI Summary
PharmaDrug Inc. initiates a project to develop a novel manufacturing method for commercial-scale cocaine production to support safe supply programs. The company files a patent for a biosynthetic chemistry method aiming to revolutionize the supply chain, potentially generating new revenue streams through global partnerships. PharmaDrug emphasizes harm reduction and the importance of biosynthetic versions of substances for a regulated pharmaceutical supply chain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
Rhea-AI Summary
PharmaDrug Inc. appoints Dr. David Kideckel as Chairman of the Board, signaling a strategic shift towards clinical trials and drug development. With a strong background in the pharmaceutical industry, Dr. Kideckel's appointment aims to drive growth and innovation within the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.39%
Tags
-
Rhea-AI Summary
PharmaDrug Inc. plans to pursue regulatory filings for a Phase I/II clinical study for its reformulated enteric coated version of orally bioavailable cepharanthine (PD-001) as a potential treatment for oncology and infectious diseases. The successful completion of manufacturing activities with Genvion Corporation enables future filings to Australia's TGA and the FDA. The Company aims to conduct clinical studies in the second quarter of 2024, with a focus on regulatory applications for human safety trials in Australia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.42%
Tags
-
Rhea-AI Summary
PharmaDrug Inc. partners with Outside The Box Capital Inc. for marketing and distribution services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.74%
Tags
Rhea-AI Summary
PharmaDrug Inc. has closed a non-brokered private placement, raising $326,000 in total gross proceeds. The company issued 6,520,000 units at a purchase price of $0.05 per unit. Each unit consists of one common share and one-half of one common share purchase warrant. The proceeds will be used for general corporate purposes, and the securities issued are subject to a hold period of four months and one day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.75%
Tags
-
Rhea-AI Summary
PharmaDrug Inc. announces share consolidation and new CFO appointment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
PharmaDrug Inc. announces Mr. Daniel Cohen will not be standing for re-election as a director and will be replaced by Mr. Robert J. Steen. Management recommends voting for the approval of Mr. Steen as a director.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary
PharmaDrug provides update on development activities for potential treatment PD-001, partnering with Genvion Corporation. Manufacturing of final product scheduled for Q1 2024. Regulatory application for safety trial in Australia in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of PHARMADRUG (LMLLF)?
The current stock price of PHARMADRUG (LMLLF) is $0.0133 as of October 15, 2024.
What is the market cap of PHARMADRUG (LMLLF)?
The market cap of PHARMADRUG (LMLLF) is approximately 2.0M.
What is PharmaDrug Inc. focused on?
PharmaDrug Inc. is focused on the research, development, and commercialization of controlled-substances, natural medicines, and previously approved drugs.
Who is PharmaDrug Inc.'s subsidiary engaged with for developing a novel cocaine manufacturing process?
PharmaDrug Inc.'s subsidiary, SecureDose Synthetics Inc., is engaged with Chiral Labs for the development of a novel cocaine manufacturing process.
What is PharmaDrug Inc.'s goal regarding safe supply programs?
PharmaDrug Inc.'s goal is to develop biosynthetic drugs for safe supply programs to combat substance abuse and contaminated street drugs.
How does PharmaDrug Inc. aim to revolutionize the pharmaceutical supply chain?
PharmaDrug Inc. aims to provide biosynthetic drugs that offer safe supply and new revenue opportunities through global partnerships and out-licensing.
PHARMADRUG INC
OTC:LMLLF
LMLLF Rankings
LMLLF Stock Data
1.95M
106.66M
0.88%
Drug Manufacturers - Specialty & Generic
Healthcare
United States of America
Toronto